Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy

NCT00784888 · clinicaltrials.gov ↗

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

OTHER: Aromatase inhibitors

Sponsor

Pfizer